Non-stimulant — multimodal SNRI
Qelbree
Viloxazine (extended release)
Non-controlled FDA approved adults
Pediatric ages 6+
How it works
Selective norepinephrine reuptake inhibitor with serotonergic activity (5-HT2C agonism, 5-HT2B antagonism).
At-a-glance
- Onset of effect
- 24–168 h
- Typical duration of effect
- 24 h
- Half-life
- ~7
- Formulations
- Oral capsule (ER)
- Adult dose range
- 200–600 mg once daily
FDA max: 600 mg/day - Pediatric dose range
- 100–400 mg/day
Common side effects
- Somnolence
- Decreased appetite
- Headache
- Nausea
- Fatigue
- Irritability
Important warnings
- Boxed warning: increased suicidal ideation (pediatric)
- Drug interactions with CYP1A2 substrates
- Caution with mania history
Notes
Newer non-stimulant (FDA-approved 2021 pediatric, 2022 adult). Faster onset than atomoxetine in some patients.
Source
Reference data is sourced from the current FDA prescribing information at DailyMed. Dose ranges, approved ages, and warnings change over time — always check the current label and consult your prescriber.